Super Religare expands Rosetta’s MicroRNA assay coverage
This article was originally published in Clinica
Rosetta Genomics has broadened its global sales network by signing an exclusive distribution deal with Super Religare Laboratories (SRL), said to be the largest Indian diagnostics network. The new partnership will see SRL make Rosetta’s range of miRview tests available in India, Saudi Arabia, Qatar and the UAE. The miRview portfolio includes a test for identifying the primary tumour site in metastatic cancer patients and patients with cancer of unknown primary, another for differentiating squamous from non-squamous non-small cell lung cancer and a test for distinguishing mesothelioma from other carcinomas in the lung. Financial details of the deal were not disclosed.